Pliant Therapeutics, Inc.
PLRX
$1.48
$0.010.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -97.46% | -83.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -97.46% | -83.69% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -100.00% | -97.46% | -83.69% |
| SG&A Expenses | 1.95% | 0.10% | 14.80% | 29.65% | 45.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.96% | 24.73% | 26.84% | 29.06% | 35.68% |
| Operating Income | -24.01% | -27.26% | -30.85% | -37.82% | -44.77% |
| Income Before Tax | -30.35% | -29.88% | -28.38% | -28.60% | -30.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.35% | -29.88% | -28.38% | -28.60% | -30.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.35% | -29.88% | -28.38% | -28.60% | -30.83% |
| EBIT | -24.01% | -27.26% | -30.85% | -37.82% | -44.77% |
| EBITDA | -24.10% | -27.38% | -31.08% | -38.26% | -45.40% |
| EPS Basic | -26.44% | -20.25% | -12.70% | 0.07% | 7.43% |
| Normalized Basic EPS | -26.44% | -20.49% | -12.91% | -0.12% | 7.26% |
| EPS Diluted | -26.44% | -20.25% | -12.70% | 0.07% | 7.49% |
| Normalized Diluted EPS | -26.44% | -20.49% | -12.91% | -0.12% | 7.26% |
| Average Basic Shares Outstanding | 3.12% | 7.82% | 13.92% | 27.23% | 39.88% |
| Average Diluted Shares Outstanding | 3.12% | 7.82% | 13.92% | 27.23% | 39.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |